Company profile: Napo Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of proprietary pharmaceuticals for gastrointestinal indications and insulin-resistant diseases, offering Mytesi (crofelemer) for chronic diarrhea in HIV/AIDS on antiretroviral therapy; NP-300, a drug candidate for moderate to severe infectious diarrhea including cholera; NP-500 for insulin-resistant diseases; CRO-IBS for diarrhea-predominant IBS; and an Investigator-Initiated Trials program on crofelemer.
Products and services
- Investigator-Initiated Trials (IIT) Program: Research-grade program supporting external researchers conducting high-quality crofelemer studies for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS
- Mytesi (crofelemer): Prescription-grade medicine for treating chronic diarrhea in patients with HIV/AIDS on antiretroviral therapy, and being studied for chemotherapy-induced overactive bowel
- NP-300: Investigational-stage drug candidate for symptomatic relief and treatment of moderate to severe diarrhea from bacterial, viral, and parasitic infections, including cholera
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Napo Pharmaceuticals
CinDome Pharma
HQ: United States
Website
- Description: Provider of treatment for the millions of people living with the devastating impact of chronic gastroparesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CinDome Pharma company profile →
Micelle BioPharma
HQ: United States
Website
- Description: Provider of integrated pharmaceutical development and marketing across a variety of products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micelle BioPharma company profile →
Inventiva
HQ: France
Website
- Description: Provider of oral small molecule therapies in development for fibrosis, lysosomal storage disorders and oncology. Pipeline includes lanifibranor (Phase III for NASH) and odiparcil (Phase IIa for MPS VI), the PanNASH research initiative, partnerships with Sino Biopharm and Hepalys Pharma, and a 240,000-compound library supporting discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inventiva company profile →
Prometheus Laboratories
HQ: United States
Website
- Description: Provider of precision gastroenterology diagnostics and tools, including: PredictrPK precision-guided dosing tests for infliximab and adalimumab using serology markers, patient variables, current dosing and machine-learning to optimize biologic therapy for IBD; Anser therapeutic drug monitoring measuring drug levels and antibodies; Monitr disease monitoring for IBD; and CDPATH prognostic tool predicting Crohn's complications risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prometheus Laboratories company profile →
Norgine
HQ: The Netherlands
Website
- Description: Provider of specialist pharmaceuticals with direct commercial presence in major European markets and infrastructure to develop, manufacture and commercialise therapies, including MOVICOL for chronic constipation; MOVIPREP and PLENVU for colon cleansing before colonoscopy; XIFAXAN for hepatic encephalopathy; FERACCRU for iron deficiency anemia; and LYMPHOSEEK for lymphatic mapping and sentinel lymph node biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Norgine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Napo Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Napo Pharmaceuticals
2.2 - Growth funds investing in similar companies to Napo Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Napo Pharmaceuticals
4.2 - Public trading comparable groups for Napo Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →